An international cohort study of cancer in systemic lupus erythematosus

S. Bernatsky, J. F. Boivin, L. Joseph, R. Rajan, A. Zoma, S. Manzi, E. Ginzler, M. Urowitz, D. Gladman, P. R. Fortin, Michelle Petri, S. Edworthy, S. Barr, C. Gordon, S. C. Bae, J. Sibley, D. Isenberg, A. Rahman, C. Aranow, M. A. Dooley & 14 others K. Steinsson, O. Nived, G. Sturfelt, G. Alarcón, J. L. Senécal, M. Zummer, J. Hanly, S. Ensworth, J. Pope, H. El-Gabalawy, T. McCarthy, Y. St. Pierre, R. Ramsey-Goldman, A. Clarke

Research output: Contribution to journalArticle

Abstract

Objective. There is increasing evidence in support of an association between systemic lupus erythematosus (SLE) and malignancy, but in earlier studies the association could not be quantified precisely. The present study was undertaken to ascertain the incidence of cancer in SLE patients, compared with that in the general population. Methods. We assembled a multisite (23 centers) international cohort of patients diagnosed as having SLE. Patients at each center were linked to regional tumor registries to determine cancer occurrence. Standardized incidence ratios (SIRs) were calculated as the ratio of observed to expected cancers. Cancers expected were determined by multiplying person-years in the cohort by the geographically matched age, sex, and calendar year-specific cancer rates, and summing over all person-years. Results. The 9,547 patients from 23 centers were observed for a total of 76,948 patient-years, with an average followup of 8 years. Within the observation interval, 431 cancers occurred. The data confirmed an increased risk of cancer among patients with SLE. For all cancers combined, the SIR estimate was 1.15 (95% confidence interval [95% CI] 1.05-1.27), for all hematologic malignancies, it was 2.75 (95% CI 2.13-3.49), and for non-Hodgkin's lymphoma, it was 3.64 (95% CI 2.63-4.93). The data also suggested an increased risk of lung cancer (SIR 1.37; 95% CI 1.05-1.76), and hepatobiliary cancer (SIR 2.60; 95% CI 1.25, 4.78). Conclusion. These results support the notion of an association between SLE and cancer and more precisely define the risk of non-Hodgkin's lymphoma in SLE. It is not yet known whether this association is mediated by genetic factors or exogenous exposures.

Original languageEnglish (US)
Pages (from-to)1481-1490
Number of pages10
JournalArthritis and Rheumatism
Volume52
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Systemic Lupus Erythematosus
Cohort Studies
Neoplasms
Confidence Intervals
Incidence
Non-Hodgkin's Lymphoma
Hematologic Neoplasms
Registries
Lung Neoplasms
Observation

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Bernatsky, S., Boivin, J. F., Joseph, L., Rajan, R., Zoma, A., Manzi, S., ... Clarke, A. (2005). An international cohort study of cancer in systemic lupus erythematosus. Arthritis and Rheumatism, 52(5), 1481-1490. https://doi.org/10.1002/art.21029

An international cohort study of cancer in systemic lupus erythematosus. / Bernatsky, S.; Boivin, J. F.; Joseph, L.; Rajan, R.; Zoma, A.; Manzi, S.; Ginzler, E.; Urowitz, M.; Gladman, D.; Fortin, P. R.; Petri, Michelle; Edworthy, S.; Barr, S.; Gordon, C.; Bae, S. C.; Sibley, J.; Isenberg, D.; Rahman, A.; Aranow, C.; Dooley, M. A.; Steinsson, K.; Nived, O.; Sturfelt, G.; Alarcón, G.; Senécal, J. L.; Zummer, M.; Hanly, J.; Ensworth, S.; Pope, J.; El-Gabalawy, H.; McCarthy, T.; St. Pierre, Y.; Ramsey-Goldman, R.; Clarke, A.

In: Arthritis and Rheumatism, Vol. 52, No. 5, 05.2005, p. 1481-1490.

Research output: Contribution to journalArticle

Bernatsky, S, Boivin, JF, Joseph, L, Rajan, R, Zoma, A, Manzi, S, Ginzler, E, Urowitz, M, Gladman, D, Fortin, PR, Petri, M, Edworthy, S, Barr, S, Gordon, C, Bae, SC, Sibley, J, Isenberg, D, Rahman, A, Aranow, C, Dooley, MA, Steinsson, K, Nived, O, Sturfelt, G, Alarcón, G, Senécal, JL, Zummer, M, Hanly, J, Ensworth, S, Pope, J, El-Gabalawy, H, McCarthy, T, St. Pierre, Y, Ramsey-Goldman, R & Clarke, A 2005, 'An international cohort study of cancer in systemic lupus erythematosus', Arthritis and Rheumatism, vol. 52, no. 5, pp. 1481-1490. https://doi.org/10.1002/art.21029
Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis and Rheumatism. 2005 May;52(5):1481-1490. https://doi.org/10.1002/art.21029
Bernatsky, S. ; Boivin, J. F. ; Joseph, L. ; Rajan, R. ; Zoma, A. ; Manzi, S. ; Ginzler, E. ; Urowitz, M. ; Gladman, D. ; Fortin, P. R. ; Petri, Michelle ; Edworthy, S. ; Barr, S. ; Gordon, C. ; Bae, S. C. ; Sibley, J. ; Isenberg, D. ; Rahman, A. ; Aranow, C. ; Dooley, M. A. ; Steinsson, K. ; Nived, O. ; Sturfelt, G. ; Alarcón, G. ; Senécal, J. L. ; Zummer, M. ; Hanly, J. ; Ensworth, S. ; Pope, J. ; El-Gabalawy, H. ; McCarthy, T. ; St. Pierre, Y. ; Ramsey-Goldman, R. ; Clarke, A. / An international cohort study of cancer in systemic lupus erythematosus. In: Arthritis and Rheumatism. 2005 ; Vol. 52, No. 5. pp. 1481-1490.
@article{61522d105ff14b0b91d5f8cedb706bfd,
title = "An international cohort study of cancer in systemic lupus erythematosus",
abstract = "Objective. There is increasing evidence in support of an association between systemic lupus erythematosus (SLE) and malignancy, but in earlier studies the association could not be quantified precisely. The present study was undertaken to ascertain the incidence of cancer in SLE patients, compared with that in the general population. Methods. We assembled a multisite (23 centers) international cohort of patients diagnosed as having SLE. Patients at each center were linked to regional tumor registries to determine cancer occurrence. Standardized incidence ratios (SIRs) were calculated as the ratio of observed to expected cancers. Cancers expected were determined by multiplying person-years in the cohort by the geographically matched age, sex, and calendar year-specific cancer rates, and summing over all person-years. Results. The 9,547 patients from 23 centers were observed for a total of 76,948 patient-years, with an average followup of 8 years. Within the observation interval, 431 cancers occurred. The data confirmed an increased risk of cancer among patients with SLE. For all cancers combined, the SIR estimate was 1.15 (95{\%} confidence interval [95{\%} CI] 1.05-1.27), for all hematologic malignancies, it was 2.75 (95{\%} CI 2.13-3.49), and for non-Hodgkin's lymphoma, it was 3.64 (95{\%} CI 2.63-4.93). The data also suggested an increased risk of lung cancer (SIR 1.37; 95{\%} CI 1.05-1.76), and hepatobiliary cancer (SIR 2.60; 95{\%} CI 1.25, 4.78). Conclusion. These results support the notion of an association between SLE and cancer and more precisely define the risk of non-Hodgkin's lymphoma in SLE. It is not yet known whether this association is mediated by genetic factors or exogenous exposures.",
author = "S. Bernatsky and Boivin, {J. F.} and L. Joseph and R. Rajan and A. Zoma and S. Manzi and E. Ginzler and M. Urowitz and D. Gladman and Fortin, {P. R.} and Michelle Petri and S. Edworthy and S. Barr and C. Gordon and Bae, {S. C.} and J. Sibley and D. Isenberg and A. Rahman and C. Aranow and Dooley, {M. A.} and K. Steinsson and O. Nived and G. Sturfelt and G. Alarc{\'o}n and Sen{\'e}cal, {J. L.} and M. Zummer and J. Hanly and S. Ensworth and J. Pope and H. El-Gabalawy and T. McCarthy and {St. Pierre}, Y. and R. Ramsey-Goldman and A. Clarke",
year = "2005",
month = "5",
doi = "10.1002/art.21029",
language = "English (US)",
volume = "52",
pages = "1481--1490",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - An international cohort study of cancer in systemic lupus erythematosus

AU - Bernatsky, S.

AU - Boivin, J. F.

AU - Joseph, L.

AU - Rajan, R.

AU - Zoma, A.

AU - Manzi, S.

AU - Ginzler, E.

AU - Urowitz, M.

AU - Gladman, D.

AU - Fortin, P. R.

AU - Petri, Michelle

AU - Edworthy, S.

AU - Barr, S.

AU - Gordon, C.

AU - Bae, S. C.

AU - Sibley, J.

AU - Isenberg, D.

AU - Rahman, A.

AU - Aranow, C.

AU - Dooley, M. A.

AU - Steinsson, K.

AU - Nived, O.

AU - Sturfelt, G.

AU - Alarcón, G.

AU - Senécal, J. L.

AU - Zummer, M.

AU - Hanly, J.

AU - Ensworth, S.

AU - Pope, J.

AU - El-Gabalawy, H.

AU - McCarthy, T.

AU - St. Pierre, Y.

AU - Ramsey-Goldman, R.

AU - Clarke, A.

PY - 2005/5

Y1 - 2005/5

N2 - Objective. There is increasing evidence in support of an association between systemic lupus erythematosus (SLE) and malignancy, but in earlier studies the association could not be quantified precisely. The present study was undertaken to ascertain the incidence of cancer in SLE patients, compared with that in the general population. Methods. We assembled a multisite (23 centers) international cohort of patients diagnosed as having SLE. Patients at each center were linked to regional tumor registries to determine cancer occurrence. Standardized incidence ratios (SIRs) were calculated as the ratio of observed to expected cancers. Cancers expected were determined by multiplying person-years in the cohort by the geographically matched age, sex, and calendar year-specific cancer rates, and summing over all person-years. Results. The 9,547 patients from 23 centers were observed for a total of 76,948 patient-years, with an average followup of 8 years. Within the observation interval, 431 cancers occurred. The data confirmed an increased risk of cancer among patients with SLE. For all cancers combined, the SIR estimate was 1.15 (95% confidence interval [95% CI] 1.05-1.27), for all hematologic malignancies, it was 2.75 (95% CI 2.13-3.49), and for non-Hodgkin's lymphoma, it was 3.64 (95% CI 2.63-4.93). The data also suggested an increased risk of lung cancer (SIR 1.37; 95% CI 1.05-1.76), and hepatobiliary cancer (SIR 2.60; 95% CI 1.25, 4.78). Conclusion. These results support the notion of an association between SLE and cancer and more precisely define the risk of non-Hodgkin's lymphoma in SLE. It is not yet known whether this association is mediated by genetic factors or exogenous exposures.

AB - Objective. There is increasing evidence in support of an association between systemic lupus erythematosus (SLE) and malignancy, but in earlier studies the association could not be quantified precisely. The present study was undertaken to ascertain the incidence of cancer in SLE patients, compared with that in the general population. Methods. We assembled a multisite (23 centers) international cohort of patients diagnosed as having SLE. Patients at each center were linked to regional tumor registries to determine cancer occurrence. Standardized incidence ratios (SIRs) were calculated as the ratio of observed to expected cancers. Cancers expected were determined by multiplying person-years in the cohort by the geographically matched age, sex, and calendar year-specific cancer rates, and summing over all person-years. Results. The 9,547 patients from 23 centers were observed for a total of 76,948 patient-years, with an average followup of 8 years. Within the observation interval, 431 cancers occurred. The data confirmed an increased risk of cancer among patients with SLE. For all cancers combined, the SIR estimate was 1.15 (95% confidence interval [95% CI] 1.05-1.27), for all hematologic malignancies, it was 2.75 (95% CI 2.13-3.49), and for non-Hodgkin's lymphoma, it was 3.64 (95% CI 2.63-4.93). The data also suggested an increased risk of lung cancer (SIR 1.37; 95% CI 1.05-1.76), and hepatobiliary cancer (SIR 2.60; 95% CI 1.25, 4.78). Conclusion. These results support the notion of an association between SLE and cancer and more precisely define the risk of non-Hodgkin's lymphoma in SLE. It is not yet known whether this association is mediated by genetic factors or exogenous exposures.

UR - http://www.scopus.com/inward/record.url?scp=20844443482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844443482&partnerID=8YFLogxK

U2 - 10.1002/art.21029

DO - 10.1002/art.21029

M3 - Article

VL - 52

SP - 1481

EP - 1490

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -